Vous n'êtes pas encore inscrit ?
InscriptionGenflow Biosciences Plc (“Genflow” or “the Company”), a UK-based biotechnology company focused
on longevity and the development of therapies to counteract the effects of aging and diseases associated
with advanced age, is pleased to announce its intention to seek a listing of its ordinary shares to the
Standard Listing segment of the London Stock Exchange.
The Company will become the first longevity biotechnology firm to list in Europe. Genflow has raised
£3.7m in an oversubscribed placing, conditional upon admission becoming effective. The flotation will
value Genflow at approximately £23.4m.
Net proceeds from the IPO will be deployed to further research into the impact of the Sirtuin-6
(“SIRT6”) gene mutation on the ageing process and its potential beneficial impact on health spans.
The move comes at a time when longevity is becoming the focus of significant clinical research and is
attracting considerable global capital. The past 15 years have seen extraordinary developments in the
understanding of the biology of ageing, on which the scientific and biotechnology community can now
act. Genflow’s Directors believe that ageing is a multifactorial, complex biological process which can
be influenced through innovative gene therapies to achieve healthier longevity.
The Company is developing gene therapies designed to target the ageing process and to reduce and
delay the incidence of age-related diseases. This will be done through novel therapeutics targeting
ageing in humans and dogs by using genetically modified adeno-associated virus (“AAV”) vectors to
deliver copies of the SIRT6 gene variant that is found in centenarians. SIRT6 has already been shown
to have significant capabilities to repair DNA damage. This will improve health spans (living healthier
for longer) and potentially, life expectancy. The Company primarily seeks to develop its lead
compound, GF-1002, a recombinant self-complementary AAV containing a transgene encoding the
cDNA (coding DNA) portion of a variant of the human SIRT6 gene found in centenarians, that has
already yielded promising pre-clinical results.
Genflow is currently undertaking pre-clinical trials which are expected to take approximately two years.
To date, research into longevity, and longevity-related investment, has primarily been centred in the
USA, where industry leaders such as Jeff Bezos and Peter Thiel have invested heavily. The UK also
has an attractive life sciences sector for investors, and the longevity market appears poised for further
significant growth.
The market opportunity in the longevity field of medicine is extremely wide and diverse because, as
life expectancy increases, so does the incidence of age-related disease. Genflow believes that interest
in treatments that seek to boost health and lifespan in tandem (and so achieve healthy ageing) will drive
growth in this space. The scale of the opportunity is driven by four key factors: a growing proportion
of people living longer; a shift in the disease burden towards age related diseases; scientific progress in
understanding the biological pathways of ageing; and the economic value of ageing well.
The economic value of treatments that tackle age related diseases comes from the prospects of both
containing costs but also the benefits from ageing well. The OECD estimates that health expenditure
will rise from 8.8% of GDP in 2015 to 10.2% by 2030 with demographic pressures driving a quarter of
this increase. Slowing the rise of age-related diseases will help to contain this. For the US, it has been
estimated that the benefits of slowing ageing such that life expectancy increases by between one and
two years is worth between $7 trillion and $38 trillion.
Dr. Eric Leire, Founder and CEO of Genflow Biosciences, said: “We are delighted to be taking an
important step for the life sciences sector by becoming the first pure play longevity company to list in
Europe. The longevity sector has enjoyed sustained growth in recent years driven by breakthrough
science and favourable demographic changes such as the growth of aging populations. Genflow’s team
of experts has a wealth of skills, experience and knowledge to guide the Company to a bright future,
and to capitalise on this opportunity for the longevity sector. We believe Genflow will unlock value for
investors whilst creating real change for the better to peoples’ lives in this exciting sector.”
Clear Capital Markets Ltd is acting as the broker for the Company.
Company Highlights
Genflow was established in order to develop therapies to allow people to live longer, healthier lives.
Genflow has assembled a team of leading experts in the longevity and gene delivery fields, with decades
of experience in the biotechnology and pharmaceutical sectors. The team benefits from a proven track
record of value creation and the important combination of technical gene therapy and entrepreneurial
skills. The Company is led, and was founded by, Dr. Eric Leire, who has two decades of experience in
cell and gene therapy and has led several gene and cell therapy companies, including Enochian
Biosciences which is listed on the Nasdaq. Dr Leire has brought together longevity sector experts to
establish a strong Scientific Advisory Board which will guide the Company’s pre-clinical and clinical
programmes and provide external perspectives to steer Genflow’s research and development strategies.
The Company’s gene therapy approach represents a shift in the management of age-related diseases as
Genflow is singularly focussed on healthy longevity and the development of a SIRT6 based therapy, as
well as a holistic approach to the nine hallmarks of ageing*. Longevity specialists typically look at just
one of the nine hallmarks, and therefore can only hope to solve 1/9th of the problem, whereas unlike its
competitors, Genflow will initially be looking at four of the nine hallmarks.
The Company is headquartered in London and has a Belgian R&D subsidiary, Genflow Biosciences
SRL (“Genflow BE”) that was established in 2020. Genflow BE’s location enables it to benefit from
the relatively low operating costs and from substantial (non diluting) grants that support its research
and development that are available from Belgium’s Wallonia region.
In addition to pre-clinical activities, Genflow seeks an earlier path to revenue with respect to Werner
Syndrome, a rare progressive disorder characterised by the appearance of unusually accelerated ageing.
Genflow intends to conduct a European Phase I/II clinical trial with Werner Syndrome patients. The
Company believes that positive clinical data will be the source of significant value creation through,
potential acquisition or licensing arrangements. Moreover, a trial in Werner Syndrome will support the
path to a specific aging indication.
Since 2020, the Company has secured investment from venture capital funds, raising gross proceeds of
£832,700 which it has used to:
• Establish a laboratory at the Gosselies Biopark in Belgium;
• Build an intellectual property portfolio through a licenced patent for SIRT6, generate an operating
version of its own SIRT6-specific AAV construct and a pipeline of gene therapy candidates (GF-1002 and GF-2001). The Company benefits from diversified and broad IP protection that includes
any product containing the SIRT6 variant and any use of it;
• Conduct initial in vitro and in vivo pre-clinical proof-of-concept studies;
• Set up a scientific advisory group;
• Define its pre-clinical and clinical development programmes; and
• Obtain SME status from the European Medicine Agency and research grants from the Wallonia
region, Belgium.
The Group has extensive relationships within the longevity field and with leading academic centres and
has entered into collaborations, including with:
• A collaboration agreement with St Anne’s University Hospital – International Clinical Research
Center, in Brno, Czech Republic in which the parties agreed to collaborate on a pre-clinical
programme to assess the effect of SIRT6 delivery on cellular senescence and metabolism in vitro
and in vivo.
• A collaboration agreement with IVEX Lab OÜ, who are based in Estonia, in which the Company
and IVEX agreed to collaborate on the development of AAV for vectors for SIRT6 therapy and on
the large-scale production of AAV vectors for in vivo study in animal models.
The management is composed of the Board of Directors and Scientific Advisory Board. The Directors
and members of the Scientific Advisory Board bring together biotech and large pharma drug
development experience with scientific expertise in regulatory pathway, clinical trials and finance.
The Board of Directors:
Dr. Yassine Bendiabdallah, Non-Executive Chairman
Dr Yassine Bendiabdallah (MPharm, PhD, IP) is a Functional Medicine Healthy Ageing Specialist and
an expert in Bio-identical Hormone therapy (BHRT). His previous academic degree as an anti-cancer
drug discovery scientist with Cancer Research UK at University College London as earned him various
distinctions and publications in peer-reviewed academic journals. After a few years in academia, he
embarked on an entrepreneurial journey and co-founded the Zen Healthcare group of pharmacies and
wellness clinics with multiple sites in London and worldwide partnerships. His current role is a clinical
director and clinician with interests including age reversal therapies, functional approaches to medicine
and intravenous micronutrient therapies. He also co-founded Pasithea Therapeutics, an innovative
biotech company and mental health group of clinics and is currently Chief Operations Officer and head
of UK Clinics. He is a director and board member of a number of companies within the healthcare
industry.
Dr. Eric Leire, Chief Executive Officer
Dr. Eric Leire, MD, MBA, brings to the Company a solid biotechnology expertise through his
experience in the pharmaceutical industry (Pfizer, Schering Plough and Pharmacia), biotechnology
(CEO of several private and public biotech companies such as APT Therapeutics and Paringenix),
academia (Research Associate at the Harvard AIDS Institute) and Private Equity (partner at Biofund
Venture Capital). He is the inventor of several patents. He also serves on the board of several
biotechnology companies such as Pherecydes (ALPH.PA), Inhatarget, Immunethep, BSIM
Therapeutics. Furthermore, Eric has been CEO of several cell and gene therapy companies such as
Enochian Biosciences (Nasdaq: ENOB) and DanDrit Biotechnologies (OTC.QB: DDRT). He has also
served as Non-Executive Director on the board of several cell and gene therapy companies such as
Genizon (Canada) or FIT Biotechnology (Finland). He holds an MD from Grenoble University and an
MBA from HEC, Paris and Kellogg, Northwestern University.
Professor Andrew Scott, Non-Executive Director
Professor Andrew J Scott is Professor of Economics and a Research Fellow at the Centre for Economic
Policy Research. Andrew previously held positions at Oxford University, the London School of
Economics and Harvard University. His MA is from Oxford, his M.Sc. from the London School of
Economics and his D.Phil from Oxford University. His research focuses on longevity, an ageing society,
and fiscal policy and debt management and has been published widely in leading journals. His book,
“The 100-Year Life” has been published in 15 languages and was runner up in both the FT/McKinsey
and Japanese Business Book of the Year Awards. He was Managing Editor for the Royal Economic
Society’s Economic Journal and Non-Executive Director for the UK’s Financial Services Authority. He
is currently on the advisory board of the UK’s Office for Budget Responsibility, the Cabinet Office
Honours Committee (Science and Technology), co-founder of The Longevity Forum and the World
Economic Forum’s council on Healthy Ageing and Longevity.
Dr. Peter King-Lewis, Non-Executive Director
Dr Peter King-Lewis studied Medicine at St Bartholomew’s Hospital in London. Prior to that he served
for ten years as a Submarine Seaman Officer and Diver in The Royal Navy. Having completed Post
Graduate Training in General Practice (St Bartholomew’s, St Thomas’, The Chelsea and Westminster
and The Priory Roehampton) he founded a Private General Practice in Central London. Continuing his
interest in Hyperbaric Medicine he was an HSE approved Medical Examiner of Divers. He has a strong
interest in Bioidentical Hormones and has practiced Acupuncture alongside more conventional
medicine. Dr King-Lewis also started and runs OfficeGP Ltd which provides Primary Care in the
workplace for a variety of companies. During the last 27 years he has also been the President of The
Independent Doctors Federation and Hon Sec, President and Trustee of the Chelsea Clinical Society.
Dr Gabrielle Silver, Non-Executive Director
Dr. Silver was formerly the Chief Executive of CHS Healthcare, the leading independent provider of
hospital discharge services and Continuing Healthcare in the UK. She oversaw the successful sale of
CHS to a trade buyer in 2021. Prior to joining CHS Healthcare, she ran Specialty Operations for
McKesson UK. She has headed the global healthcare practice at Brunswick, advising clients across the
life sciences sector with a focus on corporate positioning, crisis management and campaigns. She
previously led the GE Global Strategic Marketing Organization with a focus on Neuroscience and
Primary Care offerings. She also spent nine years in global roles within the pharmaceutical sector,
including Eisai and Bristol Myers Squibb, where she was responsible for the development, launch and
commercialisation of innovative therapies in the fields of neuroscience, psychiatry and pain
management. Having qualified as a doctor in London and practiced as an anaesthetist, she is fully
familiar with the UK public sector. Dr. Silver received her BSc in Anatomical Science from the
University of Bristol and her medical degree from the Royal Free Hospital School of Medicine in
London. She also serves as an Independent Director at Opiant Pharmaceuticals, a NASDAQ listed
biopharmaceutical company, focused on developing drugs for addiction disorders. She also serves as
non-executive director at the Royal National Orthopaedic Hospital in London.
Scientific Advisory Board:
Dr. Eric Verdin
Eric Verdin, M.D. has been Chief Executive Officer and President of Buck Institute For Age Research
since November 18, 2016. Dr. Verdin served as an Associate Director and Senior Investigator at the
Gladstone Institute of Virology and Immunology and a Professor of Medicine at the University of
California. Dr. Verdin’s laboratory work focuses on the role of protein acetylation in biological
processes, particularly in modulating the immune response. Specifically, his laboratory studies histone
deacetylase enzymes (HDACs) that remove acetyl groups from histones and non-histone proteins.
Dr. Vera Gorbunova
Vera Gorbunova, PhD is the Co-director of the Rochester Ageing Research Center, University of
Rochester New York. Dr Gorbunova is an endowed Professor of Biology at the University of Rochester
and a co-director of the Rochester Ageing Research Center. Her research is focused on understanding
the mechanisms of longevity and genome stability and on the studies of exceptionally long-lived
mammals. Her work received awards from the Ellison Medical Foundation, the Glenn Foundation,
American Federation for Ageing Research, and from the National Institutes of Health. Her work was
awarded the Cozzarelli Prize from PNAS, the prize for research on ageing from ADPS/Alianz, (France),
the Prince Hitachi Prize in Comparative Oncology, (Japan), and the Davey prize from Wilmot Cancer
Center.
Dr. Matthew Hirschey
Matthew Hirschey, PhD is an Assistant Professor in the Departments of Medicine (Division of
Endocrinology, Metabolism and Nutrition) and Pharmacology & Cancer Biology at Duke University
Medical Center and a faculty member of the Sarah W. Stedman Nutrition and Metabolism Center and
the newly formed Duke Molecular Physiology Institute. His research focuses on mitochondrial
metabolism, with a particular interest in how cells use metabolites and chemical modifications to sense
metabolism. He and his lab study the regulation of this process by a family of enzymes called sirtuins,
and how sirtuins maintain energy homeostasis. His work has appeared in several leading journals,
including Nature, Science, Cell Metabolism and Molecular Cell. He has received several awards
including an Innovator Award from the American Heart Association, a New Scholar in Ageing Award
from the Ellison Medical Foundation, and the Helmholtz Young Investigator in Diabetes (HeIDi)
Award. His work is supported by grants from the American Heart Association, the Mallinckrodt
Foundation, Friedreich’s Ataxia Research Alliance, the Ellison Medical Foundation, and the National
Institutes of Health.
Dr. Manlio Vinciguerra
Manlio Vinciguerra, PhD is a Principal Investigator at the International Clinical Research Center
(ICRC), Brno, Czech Republic. Previously he held a position of Senior Lecturer at the Institute for Liver
and Digestive Health at University College London (UCL), London, United Kingdom. He received his
PhD in Internal Medicine (2004) and research training at the University of Geneva, Switzerland, and at
the European Molecular Biology Laboratory (EMBL), in Italy and in Germany (2005-2011). He
obtained a degree in Biomolecular Sciences from the University of Catania, Italy, in 1999. Dr.
Vinciguerra unravelled important cellular signalling and epigenetics mechanisms involved in metabolic
and infectious processes, stress and ageing in the heart and in the liver, such as PI3K/AKT/mTOR
pathway and sirtuins, using a systems biology approach in cells and rodent models. He is a member of
Who’s Who in Gerontology.
Notes to Editors
Nine Hallmarks of Ageing*
First set out in a landmark paper in 2013, the nine hallmarks of ageing conceptualise the essence of
biological ageing and its underlying mechanisms. The paper found that ageing is driven by nine main
reasons:
• Genomic Instability – the mutations of human DNA that have massive repercussions over time;
• Telomere Attrition – the wearing down of the protective “caps” of human chromosomes that lead
to cellular senescence;
• Epigenetic Alterations – genes that are meant to be “off” get switched “on”, and genes that are meant
to be “on” get switched “off”;
• Loss of Proteostasis – proteins are produced incorrectly and collect in protein aggregates;
• Deregulated Nutrient – sensing pathways that are supposed to detect the level of nutrient “building
blocks” and react appropriately to those stimuli malfunction;
• Mitochondrial Dysfunction – the energy source of our cells stop working properly;
• Cellular Senescence – non-dividing ‘zombie’ cells produce inflammatory signals that harm tissues
and lead to tissue damage;
• Stem Cell Exhaustion – stem cells begin to die off due to inflammatory signalling which prevent
tissue regeneration and repair; and
• Altered Intercellular Communication – inflammatory signalling increases leading to tissue model.
